查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1684286

失眠治療市場，按治療類型、按藥物類別、按給藥途徑、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Insomnia Therapeutics Market, By Therapeutics Type, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

失眠治療市場規模在 2024 年價值 29.0232 億美元，2025 年至 2032 年期間的複合年成長率為 4.90%。

失眠治療市場-市場動態

精神健康障礙增加推動失眠治療需求

精神健康障礙的增加極大地推動了對失眠治療的需求，因為焦慮、憂鬱和壓力相關疾病等情況會導致睡眠障礙。根據世界衛生組織 (WHO) 的數據，憂鬱症影響全球超過 2.8 億人，睡眠問題是其常見症狀。美國國家心理健康研究所（NIMH）強調，患有焦慮症的人罹患慢性失眠症的風險更高。這導致失眠認知行為療法（CBT-I）被擴大採用作為一線治療方法，同時藥理學解決方案也取得了進展，例如雙重食慾素受體拮抗劑，與傳統鎮靜劑相比，其安全性更高。此外，FDA 批准的 Somryst 等數位療法正在被納入心理健康護理計劃，提供可及的非藥物治療選擇。人們越來越認知到心理健康和睡眠障礙之間的聯繫，這促使醫療保健提供者和製藥公司開發更有效和個人化的失眠療法。

失眠治療市場-關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年），全球市場預計年複合成長率約為 4.90%

根據治療類型細分，非苯二氮平類藥物預計將在 2024 年佔據最大市場佔有率

根據藥物類別細分，非苯二氮平類催眠藥是 2024 年領先的藥物類別

根據給藥途徑細分，口服是 2024 年領先的給藥途徑

從地區來看，北美是 2024 年最大的收入來源

失眠治療市場-細分分析：

全球失眠治療市場根據治療類型、藥物類別、給藥途徑、配銷通路和地區進行細分。

根據治療類型，市場分為五類：苯二氮平類藥物、非苯二氮平類藥物、抗憂鬱劑、食慾素拮抗劑、褪黑激素拮抗劑和其他。非苯二氮平類藥物因其有效性和較低的依賴風險而佔據市場主導地位。隨後，食慾素拮抗劑作為更安全的替代品逐漸受到關注。抗憂鬱藥物被廣泛用於治療合併失眠症，而苯二氮平類藥物儘管有依賴性問題但仍在使用。褪黑激素拮抗劑和其他療法可滿足特定患者的需求。

依藥物類別，市場分為六類：苯二氮平類藥物、非苯二氮平催眠藥、褪黑激素受體激動劑、食慾素受體拮抗劑、抗憂鬱劑。非苯二氮平類催眠藥物因其療效和降低的依賴風險而佔據主導地位。作為更安全的替代品，食慾素受體拮抗劑正在迅速佔領市場。抗憂鬱藥物廣泛用於治療與精神健康狀況相關的失眠症，而苯二氮平類藥物和褪黑激素受體激動劑則服務於小眾患者群體。

失眠治療市場-地理洞察

由於失眠盛行率高、精神健康障礙增加以及醫療保健基礎設施強大，北美在失眠治療市場佔據主導地位。在美國，失眠認知行為療法（CBT-I）和處方藥被廣泛採用，FDA 批准了像 daridorexant 這樣的新一代睡眠輔助藥物。歐洲緊隨其後，隨著人們對睡眠障礙的認知不斷提高，以及政府支持的心理健康計劃推動了對先進療法的需求。德國、英國和法國等國家正經歷數位治療的激增，並整合了人工智慧睡眠監測解決方案。在亞太地區，生活方式的改變、工作壓力以及城市化導致失眠負擔加重，尤其是在中國、日本和印度。這些國家中草藥和替代性睡眠療法的使用日益增多，也呈現出獨特的市場趨勢。同時，拉丁美洲和中東及非洲是新興市場，這些地區的醫療保健服務日益普及，宣傳活動不斷加強，推動人們逐步採用藥物和非藥物治療失眠的方法。

失眠治療市場-競爭格局：

失眠治療市場競爭激烈，製藥巨頭、數位健康公司和新興生技公司都專注於創新治療方案。默克公司、衛材公司和 Idorsia Pharmaceuticals 等領先公司正在推進下一代失眠藥物，包括雙食慾素受體拮抗劑，如 suvorexant 和 daridorexant，與傳統鎮靜劑相比，它們的安全性更高。同時，Jazz Pharmaceuticals 和輝瑞等公司繼續擴大其睡眠障礙藥物組合。數位治療領域也正在獲得關注，FDA 批准的解決方案，如 Pear Therapeutics 的 Somryst，透過失眠認知行為療法 (CBT-I) 提供非藥物替代方案。新創公司和科技公司正在開發人工智慧驅動的睡眠監測設備和穿戴式技術，以個人化治療方法。儘管市場取得了進步，但藥物依賴性問題、監管障礙以及草藥等替代療法的競爭等挑戰仍然影響著市場動態。策略合作、產品創新和擴大分銷網路仍然是旨在加強失眠治療市場地位的公司的關鍵策略。

最新動態：

2020 年 7 月，衛材在日本推出了 DAYVIGO(R)（lemborexant），用於治療失眠。這種雙重食慾素受體拮抗劑有助於睡眠的開始和維持。批准是基於第三階段試驗的結果，該試驗表明，與安慰劑和唑吡坦相比，該藥物可以改善睡眠，主要副作用是嗜睡、頭痛和頭暈。

2024 年 12 月，Shionogi 和 Nxera Pharma 在日本推出 QUVIVIQ(TM)（daridorexant），作為治療成人失眠的新藥物。這種口服藥物可以選擇性地阻斷食慾素受體，透過抑制過度清醒來促進睡眠。鹽野義將負責分銷和銷售。

目錄

第 1 章：失眠治療市場概述

  • 研究範圍
  • 市場估計年限

第 2 章：執行摘要

  • 市場片段
    • 失眠治療市場片段（按治療類型）
    • 失眠治療藥物市場片段（依藥物類別）
    • 失眠治療市場片段（依給藥途徑）
    • 失眠治療市場片段（按配銷通路）
    • 失眠治療市場片段（按國家/地區）
    • 失眠治療市場片段（按地區）
  • 競爭洞察

第 3 章：失眠治療關鍵市場趨勢

  • 失眠治療市場促進因素
    • 市場促進因素的影響分析
  • 失眠治療市場限制
    • 市場限制的影響分析
  • 失眠治療市場機會
  • 失眠治療市場未來趨勢

第 4 章：失眠治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景規劃
  • 規範架構分析

第 5 章：失眠治療市場：地緣政治緊張局勢升級的影響

  • 新冠肺炎疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第 6 章：失眠治療市場格局

  • 失眠治療市佔率分析，2024 年
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第 7 章：失眠治療市場 - 依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 苯二氮平類
    • 非苯二氮平類
    • 抗憂鬱藥
    • 食慾素拮抗劑
    • 褪黑素拮抗劑
    • 其他

第 8 章：失眠治療市場 - 依藥物類別

  • 概述
    • 按藥物類別進行細分佔有率分析
    • 苯二氮平類
    • 非苯二氮平類催眠藥
    • 褪黑激素受體激動劑
    • 食慾素受體拮抗劑
    • 抗憂鬱藥

第 9 章：失眠治療市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 舌下
    • 靜脈
    • 經皮
    • 鼻腔

第 10 章：失眠治療市場 - 按配銷通路

  • 概述
    • 按配銷通路進行細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局
    • 診所
    • 健康中心

第 11 章：失眠治療市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美失眠治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按治療類型）
    • 北美市場規模及預測（依藥品類別）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按配銷通路分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲失眠治療主要製造商
    • 歐洲市場規模及預測（按國家）
    • 歐洲市場規模及預測（按治療類型）
    • 歐洲市場規模及預測（依藥品類別）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（依配銷通路分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區失眠治療主要製造商
    • 亞太地區市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依治療類型）
    • 亞太地區市場規模及預測（依藥品類別）
    • 亞太地區市場規模及預測（依管理途徑分類）
    • 亞太地區市場規模及預測（依配銷通路分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲 (LATAM)
    • 概述
    • 拉丁美洲失眠治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按治療類型）
    • 拉丁美洲市場規模及預測（依藥品類別）
    • 拉丁美洲市場規模及預測（依管理途徑分類）
    • 拉丁美洲市場規模及預測（按配銷通路分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 概述
    • 中東和非洲失眠治療主要製造商
    • MEA 市場規模及預測（依國家/地區分類）
    • MEA 市場規模及預測（依治療類型）
    • MEA 市場規模及預測（依藥物類別）
    • MEA 市場規模及預測（依給藥途徑）
    • MEA 市場規模及預測（依配銷通路分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其他地區

第 12 章：失眠治療產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Astellas Pharma Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eisai Co., Ltd.
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan NV
    • Paratek Pharmaceuticals, Inc.
    • Pernix Therapeutics Holdings, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Vanda Pharmaceuticals Inc.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4883

REPORT HIGHLIGHT

Insomnia Therapeutics Market size was valued at US$ 2,902.32 Million in 2024, expanding at a CAGR of 4.90% from 2025 to 2032.

The insomnia therapeutics market focuses on treatments designed to manage and alleviate sleep disorders, particularly chronic and acute insomnia. Rising stress levels, increasing cases of mental health disorders, and lifestyle changes have significantly contributed to the growing prevalence of insomnia, with the CDC reporting that one in three adults in the U.S. does not get enough sleep. Pharmaceutical advancements, including orexin receptor antagonists like lemborexant and daridorexant, are enhancing treatment efficacy while reducing dependency risks associated with traditional benzodiazepines. Additionally, the expansion of cognitive behavioral therapy for insomnia (CBT-I) as a preferred non-pharmacological intervention is gaining traction, with digital therapeutics platforms like Somryst receiving FDA approval. However, side effects related to sedative-hypnotic drugs and the risk of dependency pose challenges to market growth. Opportunities lie in integrating AI-powered sleep monitoring devices and wearable technology, which provide personalized therapy insights. As awareness of sleep health increases, the demand for innovative and safer insomnia treatments continues to grow.

Insomnia Therapeutics Market- Market Dynamics

Rising Mental Health Disorders Driving Demand for Insomnia Therapeutics

Rising mental health disorders are significantly driving demand for insomnia therapeutics, as conditions like anxiety, depression, and stress-related disorders contribute to sleep disturbances. According to the World Health Organization (WHO), depression affects over 280 million people worldwide, with sleep issues being a common symptom. The National Institute of Mental Health (NIMH) highlights that individuals with anxiety disorders are at a higher risk of developing chronic insomnia. This has led to increased adoption of cognitive behavioral therapy for insomnia (CBT-I) as a first-line treatment, alongside advancements in pharmacological solutions such as dual orexin receptor antagonists, which offer improved safety profiles compared to traditional sedatives. Additionally, digital therapeutics like FDA-approved Somryst are being integrated into mental health care plans, providing accessible, non-drug treatment options. The growing recognition of the link between mental health and sleep disorders is pushing healthcare providers and pharmaceutical companies to develop more effective and personalized insomnia therapies.

Insomnia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2025-2032)

Based on Therapeutics Type segmentation, Nonbenzodiazepines was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, non-benzodiazepine hypnotics was the leading Drug Class in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Insomnia Therapeutics Market- Segmentation Analysis:

The Global Insomnia Therapeutics Market is segmented on the basis of Therapeutics Type, Drug Class, Route of Administration, Distribution Channel, and Region.

The market is divided into five categories based on Therapeutics Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others. Nonbenzodiazepines lead the market due to their effectiveness and lower dependency risk. Orexin antagonists follow, gaining traction as safer alternatives. Antidepressants are widely prescribed for comorbid insomnia, while benzodiazepines remain in use despite dependency concerns. Melatonin antagonists and other therapies cater to specific patient needs.

The market is divided into six categories based on Drug Class: Benzodiazepines, Non-Benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, and Antidepressants. Non-benzodiazepine hypnotics dominate due to their efficacy and reduced dependency risks. Orexin receptor antagonists are rapidly gaining market share as safer alternatives. Antidepressants are widely used for insomnia linked to mental health conditions, while benzodiazepines and melatonin receptor agonists serve niche patient segments.

Insomnia Therapeutics Market- Geographical Insights

North America dominates the insomnia therapeutics market due to high insomnia prevalence, rising mental health disorders, and strong healthcare infrastructure. The U.S., in particular, sees widespread adoption of cognitive behavioral therapy for insomnia (CBT-I) and prescription medications, with the FDA approving new-generation sleep aids like daridorexant. Europe follows closely, with increasing awareness of sleep disorders and government-backed mental health initiatives driving demand for advanced therapeutics. Countries such as Germany, the UK, and France are witnessing a surge in digital therapeutics, integrating AI-powered sleep monitoring solutions. In the Asia-Pacific region, changing lifestyles, work-related stress, and urbanization contribute to a growing insomnia burden, particularly in China, Japan, and India. The rising use of herbal and alternative sleep remedies in these countries also presents a unique market trend. Meanwhile, Latin America and the Middle East & Africa are emerging markets, where increasing healthcare access and awareness campaigns are driving gradual adoption of pharmaceutical and non-pharmaceutical insomnia treatments.

Insomnia Therapeutics Market- Competitive Landscape:

The insomnia therapeutics market is highly competitive, with pharmaceutical giants, digital health companies, and emerging biotech firms focusing on innovative treatment solutions. Leading players such as Merck & Co., Eisai Co., and Idorsia Pharmaceuticals are advancing next-generation insomnia drugs, including dual orexin receptor antagonists like suvorexant and daridorexant, which offer improved safety profiles over traditional sedatives. Meanwhile, companies like Jazz Pharmaceuticals and Pfizer continue to expand their sleep disorder drug portfolios. The digital therapeutics segment is also gaining traction, with FDA-approved solutions such as Pear Therapeutics' Somryst offering non-drug alternatives through cognitive behavioral therapy for insomnia (CBT-I). Startups and tech firms are developing AI-driven sleep monitoring devices and wearable technology to personalize treatment approaches. Despite market advancements, challenges such as drug dependency concerns, regulatory hurdles, and competition from alternative treatments like herbal remedies impact market dynamics. Strategic collaborations, product innovation, and expanding distribution networks remain key strategies for companies aiming to strengthen their market presence in insomnia therapeutics.

Recent Developments:

In July 2020, Eisai launched DAYVIGO(R) (lemborexant) in Japan, for treating insomnia. This dual orexin receptor antagonist facilitates sleep onset and maintenance. Approval was based on Phase III trials showing improved sleep compared to placebo and zolpidem, with somnolence, headache, and dizziness as main side effects.

In December 2024, Shionogi and Nxera Pharma launched QUVIVIQ(TM) (daridorexant) in Japan as a new treatment for adults with insomnia. This oral medication selectively blocks orexin receptors, promoting sleep by inhibiting excessive wakefulness. Shionogi will handle distribution and sales.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSOMNIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Paratek Pharmaceuticals, Inc.
  • Pernix Therapeutics Holdings, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.
  • Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY THERAPEUTICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Benzodiazepines
  • Nonbenzodiazepines
  • Antidepressants
  • Orexin Antagonists
  • Melatonin Antagonists
  • Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Benzodiazepines
  • Non-Benzodiazepine Hypnotics
  • Melatonin Receptor Agonists
  • Orexin Receptor Antagonists
  • Antidepressants

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Sublingual
  • Intravenous
  • Transdermal
  • Nasal

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics
  • Wellness Centers

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Insomnia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Insomnia Therapeutics Market Snippet by Therapeutics Type
    • 2.1.2. Insomnia Therapeutics Market Snippet by Drug Class
    • 2.1.3. Insomnia Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Insomnia Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Insomnia Therapeutics Market Snippet by Country
    • 2.1.6. Insomnia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Insomnia Therapeutics Key Market Trends

  • 3.1. Insomnia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Insomnia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Insomnia Therapeutics Market Opportunities
  • 3.4. Insomnia Therapeutics Market Future Trends

4. Insomnia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Insomnia Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Insomnia Therapeutics Market Landscape

  • 6.1. Insomnia Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Insomnia Therapeutics Market - By Therapeutics Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutics Type, 2024 & 2032 (%)
    • 7.1.2. Benzodiazepines
    • 7.1.3. Nonbenzodiazepines
    • 7.1.4. Antidepressants
    • 7.1.5. Orexin Antagonists
    • 7.1.6. Melatonin Antagonists
    • 7.1.7. Others

8. Insomnia Therapeutics Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Benzodiazepines
    • 8.1.3. Non-Benzodiazepine Hypnotics
    • 8.1.4. Melatonin Receptor Agonists
    • 8.1.5. Orexin Receptor Antagonists
    • 8.1.6. Antidepressants

9. Insomnia Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Sublingual
    • 9.1.4. Intravenous
    • 9.1.5. Transdermal
    • 9.1.6. Nasal

10. Insomnia Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies
    • 10.1.5. Clinics
    • 10.1.6. Wellness Centers

11. Insomnia Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Insomnia Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Insomnia Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Insomnia Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Insomnia Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Insomnia Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Insomnia Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Astellas Pharma Inc.
    • 12.2.2. Dr. Reddy's Laboratories Ltd.
    • 12.2.3. Eisai Co., Ltd.
    • 12.2.4. Lupin Limited
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. Mylan N.V.
    • 12.2.7. Paratek Pharmaceuticals, Inc.
    • 12.2.8. Pernix Therapeutics Holdings, Inc.
    • 12.2.9. Pfizer Inc.
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Sumitomo Dainippon Pharma Co., Ltd.
    • 12.2.12. Sun Pharmaceutical Industries Ltd.
    • 12.2.13. Takeda Pharmaceutical Company Limited
    • 12.2.14. Teva Pharmaceutical Industries Ltd.
    • 12.2.15. Torrent Pharmaceuticals Ltd.
    • 12.2.16. Vanda Pharmaceuticals Inc.
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us